Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18
Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Thomas Gayner Purchases 5,000 Shares of Cable One (CABO) For Markel
One of the patterns we like to see with insider buying is a long-serving Director of the company purchasing shares opportunistically. If that Director also happens to have an investing background, we like it even better. The cherry on the top is the company also buying back stock on the open market.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
40 Stocks Moving In Friday’s Mid-Day Session
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
70 Biggest Movers From Friday
Gainers
Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Mid-Afternoon Market Update: Dow Gains 500 Points; Red Robin Gourmet Burgers Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 500 points on Friday.
